- Home
- NXGL vs CGTX Comparison
NXGL vs CGTX Comparison
Compare NXGL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- CGTX
- Stock Information
- Founded
- NXGL 1997
- CGTX 2007
- Country
- NXGL United States
- CGTX United States
- Employees
- NXGL N/A
- CGTX N/A
- Industry
- NXGL Medical/Dental Instruments
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- CGTX Health Care
- Exchange
- NXGL Nasdaq
- CGTX Nasdaq
- Market Cap
- NXGL 19.4M
- CGTX 23.1M
- IPO Year
- NXGL 2021
- CGTX 2021
- Fundamental
- Price
- NXGL $2.61
- CGTX $0.33
- Analyst Decision
- NXGL
- CGTX Strong Buy
- Analyst Count
- NXGL 0
- CGTX 5
- Target Price
- NXGL N/A
- CGTX $6.13
- AVG Volume (30 Days)
- NXGL 19.6K
- CGTX 692.0K
- Earning Date
- NXGL 05-20-2025
- CGTX 05-07-2025
- Dividend Yield
- NXGL N/A
- CGTX N/A
- EPS Growth
- NXGL N/A
- CGTX N/A
- EPS
- NXGL N/A
- CGTX N/A
- Revenue
- NXGL $8,688,000.00
- CGTX N/A
- Revenue This Year
- NXGL $51.39
- CGTX N/A
- Revenue Next Year
- NXGL $36.14
- CGTX N/A
- P/E Ratio
- NXGL N/A
- CGTX N/A
- Revenue Growth
- NXGL 112.47
- CGTX N/A
- 52 Week Low
- NXGL $1.84
- CGTX $0.31
- 52 Week High
- NXGL $5.10
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- NXGL 45.77
- CGTX 35.11
- Support Level
- NXGL $2.51
- CGTX $0.40
- Resistance Level
- NXGL $2.77
- CGTX $0.47
- Average True Range (ATR)
- NXGL 0.21
- CGTX 0.03
- MACD
- NXGL 0.01
- CGTX -0.00
- Stochastic Oscillator
- NXGL 53.26
- CGTX 6.71
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.